IANALUMAB’S DUAL MODE OF ACTION: TARGETING B CELLS THROUGH ENHANCED B CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING

医学 受体 封锁 信号转导 细胞生物学 B细胞 行动方式 细胞 对偶(语法数字) 癌症研究 免疫学 内科学 抗体 生物化学 生物 艺术 文学类
作者
Catherine Wioland,Corinne Vedrine,Caroline Walter,Fanny Marque,Thomas Dannequin,Melanie Ceci,David Buffet,Cindy Schmid,Elena Degl Innocenti,Gautier Robert,Grazyna Wieczorek,David Schubert,Catriona Paape,Isabelle Isnardi
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:52 (Suppl 1): 244.1-244
标识
DOI:10.3899/jrheum.2025-0390.pv262
摘要

PV262 / #104 Poster Topic: AS24 - SLE-Treatment Background/Purpose B cells are key players in the pathogenesis of systemic lupus erythematosus (SLE), Lupus Nephritis (LN) and other systemic autoimmune diseases, supporting B cell depletion as an attractive therapeutic strategy in these patients. However, survival signals mediated by high level of B cell-activating factor (BAFF) may interfere with B cell depletion, as well as drive disease flares. Ianalumab, an investigational afucosylated monoclonal antibody targeting BAFF-receptor (BAFF-R), has been shown to deplete B cells through enhanced antibody-dependent cellular cytotoxicity (ADCC) with concurrent blockade of BAFF:BAFF-R mediated signals.[1] Here, we extensively characterize the properties of ianalumab on B cells in vitro , as well as its ability to deplete circulating and tissue B cells in B6 mice and in the spontaneous non-obese diabetic (NOD) mouse model of Sjögren’s disease (SjD). Methods The binding affinity and specificity of ianalumab were evaluated using Biacore and flow cytometry. In vitro B cell killing was assessed using peripheral blood mononuclear cells or isolated NK cells and B cells from healthy volunteers (HVs) and patients with SLE or SjD. In vitro blockade of BAFF stimulation was evaluated through competition assays with labeled BAFF, Western blots of Nuclear Factor Kappa B Subunit 2 (NF- k B2) intact and cleaved forms, B cell proliferation measured by thymidine incorporation, and quantification of IgG secretion. The efficacy of B cell depletion following administration of ianalumab in B6 and NOD mice was investigated using flow cytometry and/or histology in blood and relevant organs. Results Ianalumab demonstrated high affinity and selectivity for BAFF-R. In an ADCC assay co-culturing purified NK cells with B cells from HVs, ianalumab showed a 44-fold increased potency compared to rituximab (Figure 1A). This increased potency was also observed when NK cells from patients with SjD and SLE were tested (Figure 1B). Additionally, ianalumab effectively prevented BAFF from binding to BAFF-R expressing cells. This blockade of BAFF-R on human B cells correlated with effective inhibition of BAFF-induced cleavage of NF-κB2 (p100), proliferation and IgG production. Notably, ianalumab was able to inhibit B cell proliferation with the same potency, when induced by a BAFF trimer or 60-mer (Figure 2). In vivo , ianalumab induced a significant reduction of B cell subpopulations in blood and lymphoid organs of B6 mice. In addition, ianalumab was able to reduce B cells in the salivary glands of NOD mice, showing its ability to reduce B cells in the target organs of mice suffering from systemic autoimmunity. Figure 1. Ianalumab shows superior potency to rituximab in ADCC. A. B cells and NK cells from HVs (N=7 donors) where cocultured in the presence of ianalumab, rituximab or an irrelevant afucosylated antibody, and B cell lysis was evaluated after 60 min. B. NK cells from patients with SjD (N=3 donors) were cocultured with RI-1 cells in the presence of ianalumab or rituximab and RI-1 cell lysis was evaluated after 60 min. Figure 2. Ianalumab inhibits proliferation of human B cells from HVs (N=7 donors) stimulated by BAFF in combination with anti-IgM. Purified B cells were stimulated with BAFF 3-mer or BAFF 60-mer, in the presence of anti-IgM. Cell proliferation was measured by 3H-thymidine incorporation. Conclusions Ianalumab, through its dual mechanism of action, addresses limitations of first-generation B cell targeting therapies for autoimmune diseases by providing more potent B cell depletion and additional BAFF-R blockade on remaining B cells. Accordingly, patients with SLE ( NCT03656562 ) or SjD ( NCT02962895 ) treated with ianalumab for up to 52 weeks showed sustained reduction in disease activity in phase 2 trials.[2,3] Ongoing phase 3 studies in SjD, SLE and LN will provide further evidence on the efficacy and safety of ianalumab in larger patient populations. References: [1.] McWilliams EM. Blood Adv. 2019;3:447-60. [2.] Shen N [abstract]. Arthritis Rheumatol 2023;75 (suppl 9). [3.] Bowman SJ. Lancet 2022;399:161-71.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SPUwangshunfeng完成签到,获得积分10
刚刚
1秒前
zfr发布了新的文献求助10
1秒前
JamesPei的应助被诚心巧凡采纳,获得10
2秒前
niuzyang完成签到,获得积分10
2秒前
3秒前
仁爱诗云发布了新的文献求助10
3秒前
3秒前
shadow焓完成签到,获得积分10
5秒前
充电宝的应助被FAN采纳,获得50
6秒前
6秒前
万能图书馆的应助被HJJHJH采纳,获得10
6秒前
大橙子发布了新的文献求助10
7秒前
zddhhh发布了新的文献求助10
8秒前
8秒前
会撒娇的鸽子完成签到,获得积分20
8秒前
薛薛薛发布了新的文献求助10
9秒前
11秒前
华仔的应助被an602采纳,获得10
11秒前
Jane完成签到 ,获得积分10
13秒前
14秒前
syvshc的应助被无情的君浩采纳,获得10
14秒前
CipherSage的应助被Seraphim采纳,获得10
14秒前
huayuanxue完成签到,获得积分10
14秒前
十三发布了新的文献求助10
14秒前
百里一笑完成签到,获得积分10
15秒前
Lisztan完成签到,获得积分10
15秒前
zjb发布了新的文献求助10
16秒前
111完成签到,获得积分10
16秒前
wqjfduy完成签到,获得积分20
16秒前
科研通AI6.4的应助被现在采纳,获得10
16秒前
17秒前
中心物恺关注了科研通微信公众号
17秒前
李爱国的应助被焦一诺采纳,获得10
19秒前
楸霁完成签到,获得积分10
19秒前
Lisztan发布了新的文献求助30
21秒前
SciGPT的应助被狮子座采纳,获得10
21秒前
21秒前
22秒前
星辰大海的应助被Xin采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264